C07C 311/39
Having the nitrogen atom of at least one of the sulfonamide groups
Official title: having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
C07C311/39 (Having the nitrogen atom of at least one of the sulfonamide groups) appears on 325 US grants and 277 published applications in this corpus.
Search patents in C07C- Granted patents
- 325
- Published applications
- 277
- Assignees
- 216
- Inventors
- 1,023
- Latest grant
- 2 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 3 | 0 |
| 1977 | 3 | 0 |
| 1978 | 2 | 0 |
| 1979 | 2 | 0 |
| 1980 | 0 | 0 |
| 1981 | 1 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 4 | 0 |
| 1991 | 4 | 0 |
| 1992 | 7 | 0 |
| 1993 | 7 | 0 |
| 1994 | 4 | 0 |
| 1995 | 3 | 0 |
| 1996 | 5 | 0 |
| 1997 | 7 | 0 |
| 1998 | 16 | 0 |
| 1999 | 11 | 0 |
| 2000 | 9 | 0 |
| 2001 | 13 | 0 |
| 2002 | 19 | 13 |
| 2003 | 18 | 25 |
| 2004 | 11 | 23 |
| 2005 | 15 | 13 |
| 2006 | 10 | 13 |
| 2007 | 7 | 13 |
| 2008 | 10 | 11 |
| 2009 | 9 | 9 |
| 2010 | 6 | 14 |
| 2011 | 14 | 9 |
| 2012 | 13 | 12 |
| 2013 | 8 | 10 |
| 2014 | 11 | 17 |
| 2015 | 9 | 16 |
| 2016 | 4 | 4 |
| 2017 | 10 | 11 |
| 2018 | 7 | 5 |
| 2019 | 6 | 8 |
| 2020 | 6 | 4 |
| 2021 | 6 | 9 |
| 2022 | 4 | 12 |
| 2023 | 1 | 9 |
| 2024 | 8 | 9 |
| 2025 | 3 | 6 |
| 2026 | 7 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- USP30 inhibitors and uses thereof2 Jun 2026US 12,643,852 B2Vincere Biosciences, Inc.
- Broad spectrum anti-cancer compounds19 May 2026US 12,630,527 B2The Regents of the University of California
- Methods of treating cancer21 Apr 2026US 12,606,521 B2Institute For Cancer Research
- Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives21 Apr 2026US 12,606,522 B2OrsoBio, Inc.
- Benzenesulfonamide derivatives and uses thereof24 Feb 2026US 12,559,454 B22692372 Ontario, Inc.
- Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives16 Jul 2026US 2026/0200844 A1OrsoBio, Inc.
- Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs14 May 2026US 2026/0132103 A1The United States Government as represented by the Department of Veterans Affairs
- Phenylalanine-based lat1 inhibitors and uses thereof6 Nov 2025US 2025/0339388 A1Maxymune Therapeutics, Inc.
- Phenylalanine-based lat1 inhibitors and uses thereof16 Oct 2025US 2025/0319046 A1Maxymune Therapeutics, Inc.
- Novel benzene derivative and immunosuppression-related use thereof25 Sep 2025US 2025/0296909 A1Provibio Co., Ltd.
Most cited
By later US patents
- Modulators of ATP-binding cassette transporters157US 7,495,103 B2Vertex Pharmaceuticals Incorporated · 2009
- Sulfonamide inhibitors of aspartyl protease147US 5,585,397 AVertex Pharmaceuticals Incorporated · 1996
- Arylsulfonamido-substituted hydroxamic acids110US 5,455,258 ACiba-Geigy Corporation · 1995
- Modulators of ATP-binding cassette transporters105US 8,101,767 B2Vertex Pharmaceuticals Incorporated · 2012
- Modulators of ATP-binding cassette transporters97US 8,324,242 B2Vertex Pharmaceutical Incorporated · 2012